Avantel Ltd Q1 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/xudfpnezuqijb73h89kregmh.pdf

Key Takeaways


The Q1 Profit Reset

Dr. Abburi Vidyasagar: "In defense sector it's very difficult to exactly, know, expect or you know, the performance based on the sales revenue and profit quarter by quarter or year on year, as the procurement cycle for defense itself is slightly different from what for the civilian applications."

The 3-Year Revenue Visibility

Dr. Abburi Vidyasagar: "For the first time in the history of the company, I can confidently say that there is visibility for the next 3 years. It's the first time it's happening now."

Product Pipeline & Trials

Management: "But where Avantel is differentiated is Avantel has got 5 different competency centers... This is where Avantel stands out with respect to any of the companies, many of the companies."

R&D Investment & Capacity Build

Management: "They should all be in place by the time we meet next year AGM. They all should be in place. They should have completed development and most of them have gone through trials."

Imeds Subsidiary

Management: "We are exploring the possibility of finding a strategic investor, if required take majority stake, so that it will not be an Avantel subsidiary anymore, but Avantel can have investment."

Margins & Disclosures


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue CAGR~25% compound annual growth rateNext 3 years
Year-1 revenueApproximately ₹300 croresFY27
Year-2 revenue₹375–400 croresFY28
Year-3 revenueApproximately ₹500 croresFY29
iDEX trialsAll 5 projects offered for trials by Indian Navy and Indian ArmyStarting next month
NSIL ground stationsSupply of 9 satellite ground stations completedNext 18 months
RTS rate contract executionMost orders executedNext 18 months
RTS CMC~₹160 crores CMC5 years post-execution
SDR and iDEX development completionAll products developed and most through trialsBy next AGM
Imeds "Care at Home" developmentAI- and IoT-integrated mini-ICU completedNext one year
Imeds industrial licenseReceivedNext month
Imeds China MOUsMOUs with 4–5 companiesNext couple of months
EPS and ROCE trajectoryImprove year on yearNext 3 years
Turnover targetAt least ₹1,000 croresBy 2030

Key Metrics

MetricQ1 FY27
Revenue₹221.35 cr, declined from ₹248.48 cr in FY26
Net profit₹22.49 cr, declined from ₹259.9 cr in FY26
R&D expenditure increase₹7 cr over FY26
Depreciation increase₹7 cr over FY26 due to capex
Order book~₹1,000 cr as of AGM date, including railways, SATCOM ground stations, IMD wind profile radars, and expected DEAL order
Revenue visibility (3-year)~₹300 cr in year 1, ₹375–400 cr in year 2, ~₹500 cr in year 3, implying ~25% CAGR
RTS rate contract basic value~₹460 cr, with CMC component of ~₹160 cr over 5 years
SDR annual market opportunity~₹3,000 cr minimum across Army, Navy, Air Force; target at least 20% share
iDEX projects5 projects (3 Army, 2 Navy), ~90% completed
NSIL satellite ground stations9 ground stations, to be built in 18 months, indigenous content >50%
Fishing boat transponders supplied27,000 units completed; additional order for 5,000 units plus batteries received
R&D headcount~180 engineers
Debt-equity ratio~0.1; interest coverage ratio ~11x
Sanctioned borrowing limit~₹250 cr (fund and non-fund based), against Board permission of ₹350 cr
Trade payables₹1.78 cr, all less than 30 days; debtors receivable ₹71 cr